INHIBRX BIOSCIENCES INC (INBX) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:INBX • US45720N1037

81.99 USD
-1.31 (-1.57%)
At close: Feb 11, 2026
81.99 USD
0 (0%)
After Hours: 2/11/2026, 8:00:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

Taking everything into account, INBX scores 2 out of 10 in our fundamental rating. INBX was compared to 523 industry peers in the Biotechnology industry. INBX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. INBX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • In the past year INBX has reported negative net income.
  • INBX had a negative operating cash flow in the past year.
  • INBX had negative earnings in 4 of the past 5 years.
  • In the past 5 years INBX always reported negative operating cash flow.
INBX Yearly Net Income VS EBIT VS OCF VS FCFINBX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B 1.5B

1.2 Ratios

  • With an excellent Return On Assets value of 950.90%, INBX belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
  • INBX has a better Return On Equity (4582.06%) than 100.00% of its industry peers.
Industry RankSector Rank
ROA 950.9%
ROE 4582.06%
ROIC N/A
ROA(3y)268.02%
ROA(5y)139.35%
ROE(3y)153.62%
ROE(5y)40.8%
ROIC(3y)N/A
ROIC(5y)N/A
INBX Yearly ROA, ROE, ROICINBX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 1K

1.3 Margins

  • INBX has a Profit Margin of 843786.00%. This is amongst the best in the industry. INBX outperforms 100.00% of its industry peers.
  • INBX does not have Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) 843786%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
INBX Yearly Profit, Operating, Gross MarginsINBX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 200K 400K 600K 800K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. Health

2.1 Basic Checks

  • INBX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for INBX has been reduced compared to 1 year ago.
  • Compared to 5 years ago, INBX has less shares outstanding
  • INBX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
INBX Yearly Shares OutstandingINBX Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
INBX Yearly Total Debt VS Total AssetsINBX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

  • Based on the Altman-Z score of -1.91, we must say that INBX is in the distress zone and has some risk of bankruptcy.
  • The Altman-Z score of INBX (-1.91) is comparable to the rest of the industry.
  • A Debt/Equity ratio of 2.71 is on the high side and indicates that INBX has dependencies on debt financing.
  • INBX has a worse Debt to Equity ratio (2.71) than 79.35% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.71
Debt/FCF N/A
Altman-Z -1.91
ROIC/WACCN/A
WACC12.6%
INBX Yearly LT Debt VS Equity VS FCFINBX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

  • INBX has a Current Ratio of 4.49. This indicates that INBX is financially healthy and has no problem in meeting its short term obligations.
  • INBX has a Current ratio (4.49) which is comparable to the rest of the industry.
  • INBX has a Quick Ratio of 4.49. This indicates that INBX is financially healthy and has no problem in meeting its short term obligations.
  • INBX's Quick ratio of 4.49 is in line compared to the rest of the industry. INBX outperforms 53.54% of its industry peers.
Industry RankSector Rank
Current Ratio 4.49
Quick Ratio 4.49
INBX Yearly Current Assets VS Current LiabilitesINBX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. Growth

3.1 Past

  • INBX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -108.39%.
  • Looking at the last year, INBX shows a very negative growth in Revenue. The Revenue has decreased by -88.89% in the last year.
  • INBX shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -56.75% yearly.
EPS 1Y (TTM)-108.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%19.72%
Revenue 1Y (TTM)-88.89%
Revenue growth 3Y-69.76%
Revenue growth 5Y-56.75%
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to decrease by -14.88% on average over the next years. This is quite bad
  • The Revenue is expected to grow by 319.07% on average over the next years. This is a very strong growth
EPS Next Y-107.78%
EPS Next 2Y-42.87%
EPS Next 3Y-26.49%
EPS Next 5Y-14.88%
Revenue Next Year1200%
Revenue Next 2Y-41.42%
Revenue Next 3Y1400.52%
Revenue Next 5Y319.07%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
INBX Yearly Revenue VS EstimatesINBX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2027 2028 2029 2030 2031 100M 200M 300M
INBX Yearly EPS VS EstimatesINBX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 20 40 60 80 100

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • INBX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year INBX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
INBX Price Earnings VS Forward Price EarningsINBX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
INBX Per share dataINBX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4 -6 -8 -10

4.3 Compensation for Growth

  • INBX's earnings are expected to decrease with -26.49% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-42.87%
EPS Next 3Y-26.49%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • INBX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

INHIBRX BIOSCIENCES INC

NASDAQ:INBX (2/11/2026, 8:00:02 PM)

After market: 81.99 0 (0%)

81.99

-1.31 (-1.57%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14
Earnings (Next)03-16
Inst Owners54.56%
Inst Owner Change0.01%
Ins Owners15.57%
Ins Owner Change0%
Market Cap1.19B
Revenue(TTM)200.00K
Net Income(TTM)1.69B
Analysts43.33
Price Target12.24 (-85.07%)
Short Float %17.79%
Short Ratio7.15
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)2.1%
Min EPS beat(2)-30.11%
Max EPS beat(2)34.31%
EPS beat(4)2
Avg EPS beat(4)0.63%
Min EPS beat(4)-30.11%
Max EPS beat(4)34.31%
EPS beat(8)4
Avg EPS beat(8)429.75%
EPS beat(12)4
Avg EPS beat(12)281.7%
EPS beat(16)6
Avg EPS beat(16)208.71%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-18.62%
EPS NY rev (1m)0%
EPS NY rev (3m)-10.91%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5960.67
P/FCF N/A
P/OCF N/A
P/B 32.37
P/tB 32.37
EV/EBITDA N/A
EPS(TTM)-10.02
EYN/A
EPS(NY)-4.85
Fwd EYN/A
FCF(TTM)-9.87
FCFYN/A
OCF(TTM)-9.86
OCFYN/A
SpS0.01
BVpS2.53
TBVpS2.53
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 950.9%
ROE 4582.06%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 843786%
GM N/A
FCFM N/A
ROA(3y)268.02%
ROA(5y)139.35%
ROE(3y)153.62%
ROE(5y)40.8%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 2.71
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1.8%
Cap/Sales 23.5%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.49
Quick Ratio 4.49
Altman-Z -1.91
F-Score3
WACC12.6%
ROIC/WACCN/A
Cap/Depr(3y)185.13%
Cap/Depr(5y)152.08%
Cap/Sales(3y)528.39%
Cap/Sales(5y)321.52%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-108.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%19.72%
EPS Next Y-107.78%
EPS Next 2Y-42.87%
EPS Next 3Y-26.49%
EPS Next 5Y-14.88%
Revenue 1Y (TTM)-88.89%
Revenue growth 3Y-69.76%
Revenue growth 5Y-56.75%
Sales Q2Q%N/A
Revenue Next Year1200%
Revenue Next 2Y-41.42%
Revenue Next 3Y1400.52%
Revenue Next 5Y319.07%
EBIT growth 1Y-51.19%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year72.68%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y14.88%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y14.18%
OCF growth 3YN/A
OCF growth 5YN/A

INHIBRX BIOSCIENCES INC / INBX FAQ

What is the fundamental rating for INBX stock?

ChartMill assigns a fundamental rating of 2 / 10 to INBX.


What is the valuation status for INBX stock?

ChartMill assigns a valuation rating of 0 / 10 to INHIBRX BIOSCIENCES INC (INBX). This can be considered as Overvalued.


What is the profitability of INBX stock?

INHIBRX BIOSCIENCES INC (INBX) has a profitability rating of 2 / 10.


Can you provide the financial health for INBX stock?

The financial health rating of INHIBRX BIOSCIENCES INC (INBX) is 4 / 10.


Can you provide the expected EPS growth for INBX stock?

The Earnings per Share (EPS) of INHIBRX BIOSCIENCES INC (INBX) is expected to decline by -107.78% in the next year.